AI-Driven Ki-67 Analysis in Solid Tumors
Discover how AI-powered image analysis enhances the accuracy and reproducibility of Ki-67 scoring for tumor proliferation assessment.


Unlock deeper insights from tissue data with advanced digital pathology and image analysis.
A scanned slide is just the start. To get data you can trust, you need validated platforms, consistent workflows, and pathologists who can identify meaningful biological findings from complex tissue images.
From digitization to AI-powered quantification and spatial analysis, we help you generate reproducible, site-to-site consistent data that helps answer critical questions in your trial.
Our global lab network brings together high-throughput imaging, remote review, and multiplex capabilities to support your biomarker-driven studies across therapeutic areas, generating robust image data that can stand up to rigorous scientific and regulatory scrutiny.

Having access to multiple software programs also provides extended capabilities to offer the most relevant and efficient method to generate data.
Our image analysis software capabilities includes:

We have designed a proprietary solution for automated adjudication and short turnaround time in clinical trials where regulatory authorities request multiple readers to analyze each biopsy.
Each pathologist is equipped with a dedicated tablet to scan the sample ID inserted into the biopsy image and report on the results directly. Scores are compared by an algorithm validated specifically for each trial/scenario, triggering the request for an additional reader when necessary. The single final consensus result is then reported in the clinical trial database.
This solution offers unequaled speed and reliability when multiple readings are required in a short time frame, like, for example, biopsies for the inclusion of patients in NASH trials.
